A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Dr. Dina Radenkovic, CEO of Gameto, discusses the key considerations for bringing iPSC-based fertility treatments to market from a regulatory and manufacturing perspective.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

Dr. Dina Radenkovic, CEO of Gameto, discusses the use of iPSCs in fertility treatments, the most significant scientific hurdles they've encountered in developing and scaling these therapies ...

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

In a perfect world, every emerging biopharma company would have a clear short- and long-term vision leading up to launch.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship ...

Auguston kicked off an animated session titled “The People Factor” by outlining all the ways in which the CEO role in ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...